Becton Dickinson (BDX) announced plans to invest more than $35M and add approximately 50 new jobs to expand prefilled flush syringe manufacturing at its Columbus, Nebraska facility to increase the resiliency of the U.S. health care system. The investments will support new BD PosiFlush Prefilled Flush Syringe production lines, product innovation and operational efficiencies, enabling BD to produce hundreds of millions of additional units annually to meet growing demand from U.S. hospitals and health systems.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDX:
- Becton Dickinson receives FDA clearance for BD Veritor System for SARS-CoV-2
- Becton Dickinson, BNY, Incyte, Duolingo, Jabil: Major Stock Sales Unveiled!
- Becton, Dickinson and Co’s PUREST Study: A New Era in Urine Management
- Becton Dickinson announces BD Libertas combination product clinical trial
- Cautious Hold Rating on Becton Dickinson Amid Uncertainties in Waters Merger and Revenue Projections